Clinical Trials on Advanced Breast Cancer

Total 56854 results

National University Hospital, Singapore

Recruiting

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Advanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast Cancers

Singapore
University of California, Los Angeles
University of California, San Francisco; University of California, Irvine

Active, not recruiting

UC Health Care Planning Study

Advanced Cancer | Advance Care Planning | Advance Directives

United States
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast Cancerv

United States
Abramson Cancer Center at Penn Medicine

Active, not recruiting

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast Cancer

United States
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
University Health Network, Toronto

Active, not recruiting

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

Breast Cancer | Advanced Solid Cancers

Canada
Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
Introgen Therapeutics

Completed

Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer

Locally Advanced Breast Cancer (LABC)

United States
University of Utah
Celgene Corporation

Completed

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer (VA)

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Breast Cancer

United States
University Hospital Tuebingen

Recruiting

Praegnant Breast Cancer: Early/Advanced/Metastatic (PRAEGNANT)

Advanced/Metastatic Breast Cancer | Breast Cancer (Early Breast Cancer)

Germany
National Center of Oncology, Armenia
BRIU GmbH

Completed

"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

Armenia
Sanofi

Completed

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer

United States
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg (FINDER I)

Advanced Breast Cancer | Metastatic Breast Cancer

Japan
MedSIR
MacroGenics; Seagen Inc.

Withdrawn

Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (MARGARET)

Advanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
NBE-Therapeutics AG
Cmed Clinical Services

Terminated

NBE-002 in Patients With Advanced Solid Tumors

Triple Negative Breast Cancer | Advanced Solid Tumor | Advanced Cancer

United States
Royal Marsden NHS Foundation Trust
Pfizer; Hoffmann-La Roche

Recruiting

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM)

Advanced Breast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer

United Kingdom
Hoffmann-La Roche

Withdrawn

A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Olema Pharmaceuticals, Inc.
Novartis

Recruiting

Phase 1b Combo w/ Ribociclib and Alpelisib

Advanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast Cancer

United States, Australia
Tata Medical Center

Completed

Hypo-Fractionated Radiotherapy in Breast Cancer (HYPORT-B)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer

India
Pfizer

Completed

Palbociclib in Real World Practice

Advanced Breast Cancer | Metastatic Breast Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Breast Cancer Stage IV | Locally Advanced Breast Cancer | Metastatic Triple-Negative Breast Carcinoma | Locally Advanced Triple-Negative Breast Carcinoma

United States
Hebei Medical University Fourth Hospital

Recruiting

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Advanced Breast Cancer | HER2-positive Breast Cancer

China
Spanish Breast Cancer Research Group
AstraZeneca

Recruiting

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab (TRANSCENDER)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain
Imperial College London
Cancer Research UK

Completed

A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. (IRIS)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United Kingdom
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
Onco Medical Consult GmbH
Eli Lilly and Company; Institut fuer Frauengesundheit

Unknown

Implementing Patients´ Competence in Oral Breast Cancer Therapy (IMPACT)

Advanced Breast Cancer | Metastatic Breast Cancer
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (FINDER II)

Advanced Breast Cancer | Metastatic Breast Cancer

Belgium, Turkey, Canada, Poland, Romania, Hungary, France, Czechia
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Neovii Biotech

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Advanced Breast Cancer | Metastatic Breast Cancer

Spain, Austria, France, Germany, Italy
Novartis Pharmaceuticals

Completed

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology

China
MedSIR
AstraZeneca; Daiichi Sankyo, Inc.

Completed

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (RosHER)

Metastatic Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Spain
Carrick Therapeutics Limited
Pfizer

Recruiting

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)

Breast Cancer | Metastatic Breast Cancer | Locally Advanced Breast Cancer

Spain, United States, Turkey, Hungary
SCRI Development Innovations, LLC
Daiichi Sankyo, Inc.

Recruiting

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United States
Consorzio Oncotech

Recruiting

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Italy
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530), a PI3K δ/γ and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Georgia
Heidelberg University
Dafra Pharma; Hector-Stiftung; Monika-Kutzner Stiftung, Berlin, Germany; HEIFAN-Heidelberger...

Completed

Study of Artesunate in Metastatic Breast Cancer (ARTIC-M33/2)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Germany
Daiichi Sankyo

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast Cancer

China
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
Forward Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.

Metastatic Breast Cancer | Breast Cancer Stage I | Locally Advanced Breast Cancer | ER+ Breast Cancer

China
Fudan University

Recruiting

Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer (BCTOP-L-M01)

Breast Cancer | Advanced Breast Cancer

China
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer (PERGIQUAL)

Advanced Breast Cancer

Italy
Novartis Pharmaceuticals

Recruiting

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment (ALPINIST)

Advanced Breast Cancer

India
Genor Biopharma Co., Ltd.

Recruiting

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

Advanced Breast Cancer

Clinical Trials on Advanced Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations